{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T07:32:11Z","timestamp":1777707131858,"version":"3.51.4"},"reference-count":79,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2015\/18\/E\/NZ7\/00509"],"award-info":[{"award-number":["2015\/18\/E\/NZ7\/00509"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["798703-GEMZ-H2020-MSCA-IF-2017"],"award-info":[{"award-number":["798703-GEMZ-H2020-MSCA-IF-2017"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s13311-019-00773-w","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T13:02:58Z","timestamp":1567602178000},"page":"309-328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["N-Benzyl-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) with Hybrid Structure as a Candidate for a Broad-Spectrum Antiepileptic Drug"],"prefix":"10.1016","volume":"17","author":[{"given":"Krzysztof","family":"Kami\u0144ski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7706-2080","authenticated-orcid":false,"given":"Katarzyna","family":"Soca\u0142a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miros\u0142aw","family":"Zagaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Andres-Mach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Abram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Jakubiec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateusz","family":"Pier\u00f3g","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Nieoczym","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Rapacz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"Gawel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila V.","family":"Esguerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gniewomir","family":"Latacz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Lubelska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart\u0142omiej","family":"Szulczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Szewczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarogniew Jacek","family":"\u0141uszczki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Wla\u017a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-019-00773-w_bib1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.64.12_suppl_3.S2","article-title":"Current treatments of epilepsy","volume":"64","author":"Nadkarni","year":"2005","journal-title":"Neurology"},{"key":"10.1007\/s13311-019-00773-w_bib2","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-019-00773-w_bib3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fneur.2017.00301","article-title":"Drug-resistant epilepsy: multiple hypotheses, few answers","volume":"8","author":"Tang","year":"2017","journal-title":"Front Neurol"},{"key":"10.1007\/s13311-019-00773-w_bib4","doi-asserted-by":"crossref","unstructured":"Salpekar JA, Mula M. Common psychiatric comorbidities in epilepsy: How big of a problem is it? Epilepsy Behav https:\/\/doi.org\/10.1016\/j.yebeh.2018.07.023.","DOI":"10.1016\/j.yebeh.2018.07.023"},{"key":"10.1007\/s13311-019-00773-w_bib5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.yebeh.2008.09.004","article-title":"Stress, anxiety, depression, and epilepsy: investigating the relationship between psychological factors and seizures","volume":"14","author":"Thapar","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1007\/s13311-019-00773-w_bib6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.nbd.2018.06.017","article-title":"In search of antiepileptogenic treatments for post-traumatic epilepsy","volume":"123","author":"Saletti","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-019-00773-w_bib7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s13311-014-0266-1","article-title":"The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments","volume":"11","author":"Kaminski","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-019-00773-w_bib8","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1016\/j.bmc.2016.04.066","article-title":"Design, synthesis and anticonvulsant activity of new hybrid compounds derived from N-phenyl-2-(2,5-dioxopyrrolidin-1-yl)-propanamides and -butanamides","volume":"24","author":"Kami\u0144ski","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"10.1007\/s13311-019-00773-w_bib9","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1021\/acs.jmedchem.5b00578","article-title":"Design, synthesis, and anticonvulsant activity of new hybrid compounds derived from 2-(2,5-dioxopyrrolidin-1-yl)propanamides and 2-(2,5-dioxopyrrolidin-1-yl)butanamides","volume":"58","author":"Kami\u0144ski","year":"2015","journal-title":"J Med Chem"},{"key":"10.1007\/s13311-019-00773-w_bib10","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1016\/j.bmc.2015.03.038","article-title":"Design, synthesis and biological evaluation of new hybrid anticonvulsants derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide derivatives","volume":"23","author":"Kami\u0144ski","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"10.1007\/s13311-019-00773-w_bib11","doi-asserted-by":"crossref","first-page":"8565","DOI":"10.1021\/acs.jmedchem.7b01114","article-title":"Multifunctional Hybrid Compounds Derived from 2-(2,5-Dioxopyrrolidin-1-yl)-3-methoxypropanamides with Anticonvulsant and Antinociceptive Properties","volume":"60","author":"Abram","year":"2017","journal-title":"J Med Chem"},{"key":"10.1007\/s13311-019-00773-w_bib12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00210-017-1358-3","article-title":"Analgesic, antiallodynic, and anticonvulsant activity of novel hybrid molecules derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide in animal models of pain and epilepsy","volume":"390","author":"Rapacz","year":"2017","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1007\/s13311-019-00773-w_bib13","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1021\/acschemneuro.8b00476","article-title":"KA-11, a Novel Pyrrolidine-2,5-dione Derived Broad-Spectrum Anticonvulsant: Its Antiepileptogenic, Antinociceptive Properties and in Vitro Characterization","volume":"10","author":"Soca\u0142a","year":"2019","journal-title":"ACS Chem Neurosci"},{"key":"10.1007\/s13311-019-00773-w_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eplepsyres.2018.03.024","article-title":"Evaluation of anticonvulsant and analgesic activity of new hybrid compounds derived from N-phenyl-2-(2,5-dioxopyrrolidin-1-yl)-propanamides and -butanamides","volume":"143","author":"Rapacz","year":"2018","journal-title":"Epilepsy Res"},{"key":"10.1007\/s13311-019-00773-w_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3389\/fphar.2015.00205","article-title":"Multi-target pharmacology: possibilities and limitations of the \u201cskeleton key approach\u201d from a medicinal chemist perspective","volume":"6","author":"Talevi","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1007\/s13311-019-00773-w_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejmech.2014.01.060","article-title":"Multifunctional compounds: smart molecules for multifactorial diseases","volume":"76","author":"Bansal","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1007\/s13311-019-00773-w_bib17","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/epi.13764","article-title":"Development and pharmacologic characterization of the rat 6 Hz model of partial seizures","volume":"58","author":"Metcalf","year":"2017","journal-title":"Epilepsia"},{"issue":"suppl 4","key":"10.1007\/s13311-019-00773-w_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/epi.12296","article-title":"Issues related to development of new antiseizure treatments","volume":"54","author":"Wilcox","year":"2013","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-019-00773-w_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2004.03.009","article-title":"Kindling and status epilepticus models of epilepsy: rewiring the brain","volume":"73","author":"Morimoto","year":"2004","journal-title":"Prog Neurobiol"},{"key":"10.1007\/s13311-019-00773-w_bib20","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000360640","article-title":"Additive interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and clobazam in the mouse maximal electroshock-induced tonic seizure model\u2014an isobolographic analysis for parallel dose-response relationship curves","volume":"93","author":"Andres-Mach","year":"2014","journal-title":"Pharmacology"},{"key":"10.1007\/s13311-019-00773-w_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000430822","article-title":"Synergistic Interaction of Retigabine with Levetiracetam in the Mouse Maximal Electroshock-Induced Seizure Model: A Type II Isobolographic Analysis","volume":"96","author":"\u0141uszczki","year":"2015","journal-title":"Pharmacology"},{"key":"10.1007\/s13311-019-00773-w_bib22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000480019","article-title":"Beneficial Combination of Lacosamide with Retigabine in Experimental Animals: An Isobolographic Analysis","volume":"101","author":"\u0141uszczki","year":"2018","journal-title":"Pharmacology"},{"key":"10.1007\/s13311-019-00773-w_bib23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0013-4694(72)90177-0","article-title":"Modification of seizure activity by electrical stimulation. II. Motor seizure","volume":"32","author":"Racine","year":"1972","journal-title":"Electroencephalogr Clin Neurophysiol"},{"key":"10.1007\/s13311-019-00773-w_bib24","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/epi.12893","article-title":"Genetic background of mice strongly influences treatment resistance in the 6 Hz seizure model","volume":"56","author":"Leclercq","year":"2015","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-019-00773-w_bib25","doi-asserted-by":"crossref","unstructured":"Litchfield JT, Jr., Wilcoxon F. A simplified method of evaluating dose-effect experiments. 1949;96(2):99\u2013113.","DOI":"10.1016\/S0022-3565(25)03549-9"},{"key":"10.1007\/s13311-019-00773-w_bib26","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00210-008-0305-8","article-title":"Interactions of tiagabine with ethosuximide in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis for non-parallel dose-response relationship curves","volume":"378","author":"\u0141uszczki","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1007\/s13311-019-00773-w_bib27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.pnpbp.2012.07.001","article-title":"Effect of ACEA\u2014a selective cannabinoid CB1 receptor agonist on the protective action of different antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model","volume":"39","author":"Andres-Mach","year":"2012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1007\/s13311-019-00773-w_bib28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.pnpbp.2006.11.020","article-title":"Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy","volume":"31","author":"\u0141uszczki","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1007\/s13311-019-00773-w_bib29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00210-007-0144-z","article-title":"Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application","volume":"375","author":"\u0141uszczki","year":"2007","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1007\/s13311-019-00773-w_bib30","series-title":"Drug synergism and dose \u2013 effect data analysis","author":"Tallarida","year":"2000"},{"key":"10.1007\/s13311-019-00773-w_bib31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000134913","article-title":"Une nouvelle methode simple pour explorer l'action \u2018tranquilistante\u2019: le test de la cheminee","volume":"3","author":"Boissier","year":"1960","journal-title":"Med Exp (Basel)"},{"key":"10.1007\/s13311-019-00773-w_bib32","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.fitote.2016.09.020","article-title":"Influence of xanthotoxin (8-methoxypsoralen) on the anticonvulsant activity of various novel antiepileptic drugs against maximal electroshock-induced seizures in mice","volume":"115","author":"Zagaja","year":"2016","journal-title":"Fitoterapia"},{"key":"10.1007\/s13311-019-00773-w_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054166","article-title":"Validation of the zebrafish pentylenetetrazol seizure model: locomotor versus electrographic responses to antiepileptic drugs","volume":"8","author":"Afrikanova","year":"2013","journal-title":"PLoS One"},{"key":"10.1007\/s13311-019-00773-w_bib34","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s11064-019-02735-2","article-title":"Anticonvulsant activity of pterostilbene in zebrafish and mouse acute seizure tests","volume":"44","author":"Nieoczym","year":"2019","journal-title":"Neurochem Res"},{"key":"10.1007\/s13311-019-00773-w_bib35","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1523\/JNEUROSCI.06-07-02064.1986","article-title":"3H-batrachotoxinin-A benzoate binding to voltage-sensitive sodium channels: inhibition by the channel blockers tetrodotoxin and saxitoxin","volume":"6","author":"Brown","year":"1986","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-019-00773-w_bib36","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1073\/pnas.79.11.3656","article-title":"[3H]nitrendipine-labeled calcium channels discriminate inorganic calcium agonists and antagonists","volume":"79","author":"Gould","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-019-00773-w_bib37","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0022-3565(25)24904-7","article-title":"(-)-[3H] desmethoxyverapamil labels multiple calcium channel modulator receptors in brain and skeletal muscle membranes: differentiation by temperature and dihydropyridines","volume":"237","author":"Reynolds","year":"1986","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1007\/s13311-019-00773-w_bib38","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0014-2999(85)90768-X","article-title":"[3H]diltiazem binding to calcium channel antagonists recognition sites in rat cerebral cortex","volume":"111","author":"Schoemaker","year":"1985","journal-title":"Eur J Pharmacol"},{"key":"10.1007\/s13311-019-00773-w_bib39","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1523\/JNEUROSCI.08-09-03354.1988","article-title":"Omega-conotoxin GVIA binding to a high-affinity receptor in brain: characterization, calcium sensitivity, and solubilization","volume":"8","author":"Wagner","year":"1988","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-019-00773-w_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0014-2999(91)90063-V","article-title":"[3H]CGP 39653: a new N-methyl-D-aspartate antagonist radioligand with low nanomolar affinity in rat brain","volume":"192","author":"Sills","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.1007\/s13311-019-00773-w_bib41","first-page":"521","article-title":"Pharmacological study on recombinant human GABA-A receptor complex containing alpha5 (leucine155 to valine) combined with beta3gamma2s subunits","volume":"22","author":"Wang","year":"2001","journal-title":"Acta Pharmacol Sin"},{"key":"10.1007\/s13311-019-00773-w_bib42","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/j.1471-4159.1990.tb04905.x","article-title":"Ion and temperature effects on the binding of gamma-aminobutyrate to its receptors and the high-affinity transport system","volume":"54","author":"Shank","year":"1990","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-019-00773-w_bib43","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1089\/adt.2010.0331","article-title":"Identification of human Ether-a-go-go related gene modulators by three screening platforms in an academic drug-discovery setting","volume":"8","author":"Huang","year":"2010","journal-title":"Assay Drug Dev Technol"},{"key":"10.1007\/s13311-019-00773-w_bib44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejphar.2005.02.045","article-title":"Cloning and functional characterization of dog transient receptor potential vanilloid receptor-1 (TRPV1)","volume":"513","author":"Phelps","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1007\/s13311-019-00773-w_bib45","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0026-895X(25)10492-6","article-title":"Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors","volume":"48","author":"Felder","year":"1995","journal-title":"Mol Pharmacol"},{"key":"10.1007\/s13311-019-00773-w_bib46","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.bbrc.2017.07.109","article-title":"Valproic acid inhibits TTX-resistant sodium currents in prefrontal cortex pyramidal neurons","volume":"491","author":"Szulczyk","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1007\/s13311-019-00773-w_bib47","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1039\/C8MD00313K","article-title":"Search for a 5-CT alternative. In vitro and in vivo evaluation of novel pharmacological tools: 3-(1-alkyl-1H-imidazol-5-yl)-1H-indole-5-carboxamides, low-basicity 5-HT7 receptor agonists","volume":"9","author":"Latacz","year":"2018","journal-title":"Medchemcomm"},{"key":"10.1007\/s13311-019-00773-w_bib48","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(01)00302-3","article-title":"Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy","volume":"47","author":"Barton","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1007\/s13311-019-00773-w_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2009.03.025","article-title":"Preclinical assessment of proconvulsant drug activity and its relevance for predicting adverse events in humans","volume":"610","author":"L\u00f6scher","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1007\/s13311-019-00773-w_bib50","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1080\/00207454.2018.1481064","article-title":"Neuropathological profile of the pentylenetetrazol (PTZ) kindling model","volume":"128","author":"Samokhina","year":"2018","journal-title":"Int J Neurosci"},{"key":"10.1007\/s13311-019-00773-w_bib51","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pnpbp.2003.09.026","article-title":"Anticonvulsant and antiepileptogenic effects of GABAA receptor ligands in pentylenetetrazole-kindled mice","volume":"28","author":"Hansen","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1007\/s13311-019-00773-w_bib52","doi-asserted-by":"crossref","first-page":"27420","DOI":"10.1038\/srep27420","article-title":"Synaptic vesicle glycoprotein 2A (SV2A) regulates kindling epileptogenesis via GABAergic neurotransmission","volume":"6","author":"Tokudome","year":"2016","journal-title":"Sci Rep"},{"key":"10.1007\/s13311-019-00773-w_bib53","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1006\/nbdi.2000.0300","article-title":"Differential involvement of L-type calcium channels in epileptogenesis of rat hippocampal slices during ontogenesis","volume":"7","author":"Kohling","year":"2000","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-019-00773-w_bib54","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11010-016-2678-1","article-title":"Neurochemical modulation involved in the beneficial effect of liraglutide, GLP-1 agonist on PTZ kindling epilepsy-induced comorbidities in mice","volume":"415","author":"Koshal","year":"2016","journal-title":"Mol Cell Biochem"},{"key":"10.1007\/s13311-019-00773-w_bib55","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3389\/fnbeh.2017.00203","article-title":"Neuronal Nitric Oxide Synthase Contributes to PTZ Kindling-Induced Cognitive Impairment and Depressive-Like Behavior","volume":"11","author":"Zhu","year":"2017","journal-title":"Front Behav Neurosci"},{"key":"10.1007\/s13311-019-00773-w_bib56","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.yebeh.2017.03.019","article-title":"Effects of agomelatine on pentylenetetrazole-induced kindling, kindling-associated oxidative stress, and behavioral despair in mice and modulation of its actions by luzindole and 1-(m-chlorophenyl) piperazine","volume":"72","author":"Azim","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1007\/s13311-019-00773-w_bib57","doi-asserted-by":"crossref","unstructured":"Schwabe K, Ebert U. Animal models of epilepsy. In: Animal models of neuropsychiatric diseases. Imperial College Press, 2006, pp. 75\u2013117.","DOI":"10.1142\/9781860948022_0002"},{"key":"10.1007\/s13311-019-00773-w_bib58","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.pnpbp.2011.07.001","article-title":"Effects of WIN 55,212-2 mesylate (a synthetic cannabinoid) on the protective action of clonazepam, ethosuximide, phenobarbital and valproate against pentylenetetrazole-induced clonic seizures in mice","volume":"35","author":"\u0141uszczki","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1007\/s13311-019-00773-w_bib59","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0920-1211(91)90062-K","article-title":"The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models","volume":"8","author":"L\u00f6scher","year":"1991","journal-title":"Epilepsy Res"},{"key":"10.1007\/s13311-019-00773-w_bib60","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1528-1167.2011.03024.x","article-title":"Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma","volume":"52","author":"L\u00f6scher","year":"2011","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-019-00773-w_bib61","doi-asserted-by":"crossref","first-page":"17716","DOI":"10.1074\/jbc.M207582200","article-title":"The anticonvulsant valproate increases the turnover rate of gamma-aminobutyric acid transporters","volume":"278","author":"Whitlow","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-019-00773-w_bib62","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/j.1476-5381.1995.tb16388.x","article-title":"Peripheral GABAA receptor-mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation","volume":"116","author":"Lee","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1007\/s13311-019-00773-w_bib63","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/WCO.0b013e328042bae0","article-title":"Emerging epilepsy models: insights from mice, flies, worms and fish","volume":"20","author":"Baraban","year":"2007","journal-title":"Curr Opin Neurol"},{"key":"10.1007\/s13311-019-00773-w_bib64","doi-asserted-by":"crossref","first-page":"e81634","DOI":"10.1371\/journal.pone.0081634","article-title":"Insights from zebrafish and mouse models on the activity and safety of ar-turmerone as a potential drug candidate for the treatment of epilepsy","volume":"8","author":"Orellana-Paucar","year":"2013","journal-title":"PLoS One"},{"key":"10.1007\/s13311-019-00773-w_bib65","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1021\/acschemneuro.8b00060","article-title":"Zebrafish-Based Discovery of Antiseizure Compounds from the Red Sea: Pseurotin A2 and Azaspirofuran A","volume":"9","author":"Copmans","year":"2018","journal-title":"ACS Chem Neurosci"},{"key":"10.1007\/s13311-019-00773-w_bib66","first-page":"773","article-title":"Identification of compounds with anti-convulsant properties in a zebrafish model of epileptic seizures","volume":"5","author":"Baxendale","year":"2012","journal-title":"Dis Model Mech"},{"key":"10.1007\/s13311-019-00773-w_bib67","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1021\/cn400140e","article-title":"Tanshinone IIA exhibits anticonvulsant activity in zebrafish and mouse seizure models","volume":"4","author":"Buenafe","year":"2013","journal-title":"ACS Chem Neurosci"},{"key":"10.1007\/s13311-019-00773-w_bib68","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.yebeh.2012.02.020","article-title":"Anticonvulsant activity of bisabolene sesquiterpenoids of Curcuma longa in zebrafish and mouse seizure models","volume":"24","author":"Orellana-Paucar","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1007\/s13311-019-00773-w_bib69","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.yebeh.2016.11.016","article-title":"Pharmacology of cannabinoids in the treatment of epilepsy","volume":"70","author":"Gaston","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1007\/s13311-019-00773-w_bib70","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1021\/cn5000524","article-title":"Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability","volume":"5","author":"Iannotti","year":"2014","journal-title":"ACS Chem Neurosci"},{"key":"10.1007\/s13311-019-00773-w_bib71","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the dravet Syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-019-00773-w_bib72","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.neuropharm.2019.01.002","article-title":"Preclinical safety and efficacy of cannabidivarin for early life seizures","volume":"148","author":"Huizenga","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-019-00773-w_bib73","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.eplepsyres.2006.09.008","article-title":"Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery","volume":"73","author":"Taylor","year":"2007","journal-title":"Epilepsy Res"},{"key":"10.1007\/s13311-019-00773-w_bib74","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.neulet.2013.11.017","article-title":"Presynaptic inhibitory actions of pregabalin on excitatory transmission in superficial dorsal horn of mouse spinal cord: further characterization of presynaptic mechanisms","volume":"558","author":"Matsuzawa","year":"2014","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-019-00773-w_bib75","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1528-1167.2011.03109.x","article-title":"Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy","volume":"52","author":"Hanada","year":"2011","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-019-00773-w_bib76","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bcp.2017.09.015","article-title":"Auxiliary subunits of AMPA receptors: The discovery of a forebrain-selective antagonist, LY3130481\/CERC-611","volume":"147","author":"Kato","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1007\/s13311-019-00773-w_bib77","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuropharm.2017.07.028","article-title":"Electroencephalographic, cognitive, and neurochemical effects of LY3130481 (CERC-611), a selective antagonist of TARP-gamma8-associated AMPA receptors","volume":"126","author":"Witkin","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-019-00773-w_bib78","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/nm.4221","article-title":"Forebrain-selective AMPA-receptor antagonism guided by TARP gamma-8 as an antiepileptic mechanism","volume":"22","author":"Kato","year":"2016","journal-title":"Nat Med"},{"key":"10.1007\/s13311-019-00773-w_bib79","series-title":"Drug-like properties\u2014concepts, structure design and methods: from ADME to toxicity optimization","author":"Kerns","year":"2016"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-019-00773-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-019-00773-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923013995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923013995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-019-00773-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:57:25Z","timestamp":1761807445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923013995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1878747923013995"],"URL":"https:\/\/doi.org\/10.1007\/s13311-019-00773-w","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N-Benzyl-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) with Hybrid Structure as a Candidate for a Broad-Spectrum Antiepileptic Drug","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-019-00773-w","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}